Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Thorac Cancer. 2024 Feb;15(5):386-393. doi: 10.1111/1759-7714.15202. Epub 2023 Dec 26.
This study aimed to investigate the clinicopathological features and prognostic indicators of primary pulmonary adenoid cystic carcinoma (PACC).
Clinical data were collected from 64 primary PACC patients and analyzed retrospectively at the Tianjin Medical University General Hospital, the West China Hospital of Sichuan University, the First Affiliated Hospital of Guangxi Medical University, and the Bishan Hospital of Chongqing Medical University from January 2003 to August 2023. The 64 patients (28 males and 36 females) were aged from 20 to 73 years, with a median age of 49 years and an average age of 49.3 years.
Immunohistochemical staining showed that the tumors expressed CK7, S-100 protein, CK5/6, CD117, and p63. Seven patients underwent fluorescence in situ hybridization (FISH) testing and three were found to have myeloblastosis (MYB) gene translocation. In total, 53 patients underwent surgery, among whom 31 received only surgery and 22 received both surgery and postoperative chemoradiotherapy. In addition, 10 patients received chemoradiotherapy only, while one patient underwent treatment with traditional Chinese medicine. The overall survival rates in the first, third, and fifth years were 98.4%, 95.3%, and 87.5%, respectively.
Prognostic analysis revealed that age, tumor size, lymph node metastasis status, margin status, and choice of treatment modality significantly influenced the patients' prognosis.
本研究旨在探讨原发性肺腺样囊性癌（PACC）的临床病理特征和预后指标。
回顾性收集 2003 年 1 月至 2023 年 8 月期间，天津医科大学总医院、四川大学华西医院、广西医科大学第一附属医院和重庆市璧山区人民医院共 64 例原发性 PACC 患者的临床资料，进行分析。64 例患者中，男性 28 例，女性 36 例；年龄 20～73 岁，中位年龄 49 岁，平均年龄 49.3 岁。
免疫组织化学染色显示肿瘤表达 CK7、S-100 蛋白、CK5/6、CD117 和 p63。7 例行荧光原位杂交（FISH）检测，其中 3 例存在髓母细胞瘤（MYB）基因易位。共 53 例行手术治疗，其中单纯手术 31 例，手术联合术后放化疗 22 例。10 例患者仅接受放化疗，1 例患者接受中医治疗。患者 1、3、5 年的总生存率分别为 98.4%、95.3%和 87.5%。
预后分析显示，年龄、肿瘤大小、淋巴结转移状态、切缘状态和治疗方式的选择显著影响患者的预后。
